CASI Pharmaceuticals, Inc. (CASI) Financial Statements (2023 and Earlier)

Company Profile

Business Address 9620 MEDICAL CENTER DR
ROCKVILLE, MD 20850
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments48,572 54,24685,11743,49027,093
Cash and cash equivalents38,704 53,62184,20543,49027,093
Short-term investments9,868 625912  
Receivables9,803 1,293   
Inventory, net of allowances, customer advances and progress billings1,907 4,542283  
Inventory1,907 4,542283  
Other undisclosed current assets1,688 1,4207,165322356
Total current assets:61,970 61,50192,56543,81227,449
Noncurrent Assets
Operating lease, right-of-use asset9,107 8,708
Property, plant and equipment12,712 9851,7511,047230
Long-term investments and receivables40,128 14,038   
Long-term investments40,128 14,038   
Intangible assets, net (including goodwill)12,203 16,89518,785  
Intangible assets, net (excluding goodwill)12,203 16,89518,785  
Other noncurrent assets2,178 50431024234
Total noncurrent assets:76,328 41,13020,8451,289264
TOTAL ASSETS:138,298 102,631113,41045,10127,713
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,125 7,9472,3742,8341,316
Accounts payable4,789 5,1139682,0881,065
Accrued liabilities  2,8341,406746251
Employee-related liabilities3,336     
Debt   1,499  
Due to related parties    2,228 
Other liabilities60     
Other undisclosed current liabilities5,001     
Total current liabilities:13,186 7,9473,8745,0621,316
Noncurrent Liabilities
Long-term debt and lease obligation    1,4991,491
Long-term debt, excluding current maturities    1,4991,491
Liabilities, other than long-term debt14,325 1,01974 4,122
Other liabilities14,325 1,01974  
Derivative instruments and hedges, liabilities     4,122
Other undisclosed noncurrent liabilities2,828     
Total noncurrent liabilities:17,153 1,019741,4995,614
Total liabilities:30,339 8,9663,9486,5616,929
Temporary equity, carrying amount23,457 20,670   
Stockholders' equity
Stockholders' equity attributable to parent84,502 72,995109,46238,54020,784
Common stock1,399 979954699603
Treasury stock, value(8,034) (8,034)(8,034)(8,034)(8,034)
Additional paid in capital694,826 606,686596,711498,577470,147
Accumulated other comprehensive income (loss)1,954 (2,728)(1,226)  
Accumulated deficit(605,643) (523,908)(478,941)(452,702)(441,932)
Total stockholders' equity:84,502 72,995109,46238,54020,784
TOTAL LIABILITIES AND EQUITY:138,298 102,631113,41045,10127,713

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues30,168 4,131   
Cost of revenue(12,557) (8,556)(316)  
Cost of goods and services sold(12,557) (3,935)   
Gross profit:17,611 (4,425)(316)  
Operating expenses(59,448) (42,533)(26,875)(10,869)(9,421)
Operating loss:(41,837) (46,958)(27,191)(10,869)(9,421)
Nonoperating income879 822   
Foreign currency transaction gain, before tax321 817   
Other nonoperating income558 5   
Interest and debt expense(3) (6)(8)  
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes  780(273)99 
Loss from continuing operations before equity method investments, income taxes:(40,961) (45,362)(27,472)(10,770)(9,421)
Other undisclosed income from continuing operations before income taxes5,119     
Net loss:(35,842) (45,362)(27,472)(10,770)(9,421)
Net income attributable to noncontrolling interest700 395   
Other undisclosed net loss attributable to parent(1,512) (1,065)  (33)
Net loss available to common stockholders, diluted:(36,654) (46,032)(27,472)(10,770)(9,453)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(35,842) (45,362)(27,472)(10,770)(9,421)
Other undisclosed comprehensive income (loss)1,977 (1,501)   
Comprehensive loss:(33,865) (46,863)(27,472)(10,770)(9,421)
Comprehensive income, net of tax, attributable to noncontrolling interest88 395   
Other undisclosed comprehensive loss, net of tax, attributable to parent   (1,226)  
Comprehensive loss, net of tax, attributable to parent:(33,777) (46,468)(28,698)(10,770)(9,421)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: